Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment
Cancers · 24.01.2023 · 15 (3) · 724
DOI: 10.3390/cancers15030724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.01.2023. Verfasst von Hiroyoshi Y Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 529 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Okayama University.
Abstract (Originalsprache)
Pancreatic cancer is notorious for its dismal prognosis. The enhanced permeability and retention (EPR) effect theory posits that nanomedicines (therapeutics in the size range of approximately 10–200 nm) selectively accumulate in tumors. Nanomedicine has thus been suggested to be the “magic bullet”—both effective and safe—to treat pancreatic cancer. However, the densely fibrotic tumor microenvironment of pancreatic cancer impedes nanomedicine delivery. The EPR effect is thus insufficient to achieve a significant therapeutic effect. Intratumoral fibrosis is chiefly driven by aberrantly activated fibroblasts and the extracellular matrix (ECM) components secreted. Fibroblast and ECM abnormalities offer various potential targets for therapeutic intervention. In this review, we detail the diverse strategies being tested to overcome the fibrotic barriers to nanomedicine in pancreatic cancer. Strategies that target the fibrotic tissue/process are discussed first, which are followed by strategies to optimize nanomedicine design. We provide an overview of how a deeper understanding, increasingly at single-cell resolution, of fibroblast biology is revealing the complex role of the fibrotic stroma in pancreatic cancer pathogenesis and consider the therapeutic implications. Finally, we discuss critical gaps in our understanding and how we might better formulate strategies to successfully overcome the fibrotic barriers in pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama-shi 700-8530, Okayama, Japan.
- Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama-shi 700-8530, Okayama, Japan.
- Department of Pathology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya-shi 466-8550, Aichi, Japan.
- Division of Gastroenterology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai-shi 980-8574, Miyagi, Japan.
ORCID-Profile: Hiroyoshi Y Tanaka, Atsushi Enomoto, Atsushi Masamune, Mitsunobu R Kano
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Okayama University
- Inamori Foundation
- Hokuto Foundation for Bioscience
- Research Foundation for Pharmaceutical Sciences
- Sanyo Broadcasting Foundation
- Pancreas Research Foundation of Japan
Zitieren
APA
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023). Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment. Cancers, 15(3), 724. https://doi.org/10.3390/cancers15030724
Vancouver
Tanaka HY, Nakazawa T, Enomoto A, Masamune A, Kano MR. Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment. Cancers. 2023;15(3):724. doi:10.3390/cancers15030724
BibTeX
@article{Tanaka2023,
author = {Tanaka, Hiroyoshi Y and Nakazawa, Takuya and Enomoto, Atsushi and Masamune, Atsushi and Kano, Mitsunobu R},
title = {Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {724},
doi = {10.3390/cancers15030724}
}
EUVIMED